Oral etoposide for refractory and relapsed neuroblastoma

Journal of Clinical Oncology

Volumn 17, Issue 10, 1999, Pages 3221-3225

  Kushner, Brian H ^a   Kramer, Kim ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ETOPOSIDE;

ARTICLE; BONE MARROW BIOPSY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; NEUROBLASTOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 0032888252     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.10.3221     Document Type: Article

References (24)

1. Matthay KK: Neuroblastoma: Biology and therapy. Oncology 11:1857-1866, 1997
2. Cheung NKC, Heller G: Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 9:1050-1058, 1991
3. Ladenstein R, Lasset C, Hartmann O, et al: Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over 1 year of age at diagnosis: A report from the European Group for Bone Marrow Transplantation. J Clin Oncol 11:2230-2341, 1993
4. Hainsworth JD, Greco FA: Etoposide: Twenty years later. Ann Oncol 6:325-341, 1995
5. Davidson A, Lewis I, Pearson ADJ, et al: 21-day schedule oral etoposide in children: A feasibility study. Eur J Cancer 29A:2223-2225, 1993
6. Chamberlain MC: Recurrent brainstem gliomas treated with oral VP-16. J Neurooncol 15:133-139, 1993
7. Mathew P, Ribeiro RC, Sonnichsen D, et al: Phase I study of oral etoposide in children with refractory solid tumors. J Clin Oncol 12:1452-1457, 1994
8. Cappelli C, Hartmann O, Pein F, et al: Efficacy of palliative oral etoposide in metastatic neuroblastoma relapsing after high-dose chemotherapy. Med Pediatr Oncol 25:319, 1995 (abstr)
9. Chamberlain MC, Grafe MR: Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide. J Clin Oncol 13:2072-2076, 1995
10. Ashley DM, Meier L, Kerby T, et al: Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 14:1922-1927, 1996
11. Davidson A, Gowing R, Lowis S, et al: Phase II study of 21 day schedule oral etoposide in children. Eur J Cancer 33:1816-1822, 1997
12. Cheung N-KV, Heller G, Kushner BH, et al: Detection of metastatic neuroblastoma in bone marrow: When is routine marrow histology insensitive? J Clin Oncol 15:2807-2817, 1997
13. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993
14. Greco FA, Hainsworth JD: Prolonged administration of low-daily-dose etoposide: A superior dosing schedule? Cancer Chemother Pharmacol 34:S101-S104, 1994
15. Kushner BH, LaQuaglia MP, Bonilla MA, et al: Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 12:2607-2613, 1994
16. Stram DO, Matthay KK, O'Leary M, et al: Consolidation chemoradiotherapy and autologous bone marrow transplantation vs continued chemotherapy for metastatic neuroblastoma: A report of two concurrent Children's Cancer Group studies. J Clin Oncol 14:2417-2426, 1996
17. Matthay KK, Harris R, Reynolds CP, et al: Improved event-free survival (efs) for autologous bone marrow transplantation (abmt) vs chemotherapy in neuroblastoma: A phase III randomized Children's Cancer Group (CCG) study. Proc Am Soc Clin Oncol 17:525a, 1998 (abstr 2018)
18. Villablanca JG, Khan AA, Avramis VI, et al: Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 134:894-901, 1995
19. Cheung NKV, Kushner BH, Cheung IY, et al: Anti-GD2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 16:3053-3060, 1998
20. Kushner BH, Cheung NKV, Kramer K, et al: Neuroblastoma and treatment-related myelodysplasia/leukemia: The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 16:3880-3889, 1998
21. Yagita M, Ieki Y, Onishi R, et al: Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer. Int J Cancer 13:91-96, 1998
22. Stine KC, Saylors RL, Sawyer JR, et al: Secondary acute myelogenous leukemia following safe exposure to etoposide. J Clin Oncol 15:1583-1586, 1997
23. Ladisch S, Gadner H, Arico M, et al: LCH-1 : A randomized trial of etoposide versus vinblastine in disseminated Langerhans cell histiocytosis. Med Pediatr Oncol 23:107-110, 1994
24. Smith MA, Rubinstein L, Anderson JR, et al: Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 17:569-577, 1999